Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Chan-Hee Jung  (Jung CH) 13 Articles
Thyroid
Big Data Articles (National Health Insurance Service Database)
Graves’ Disease and the Risk of End-Stage Renal Disease: A Korean Population-Based Study
Yoon Young Cho, Bongseong Kim, Dong Wook Shin, Hye Ryoun Jang, Bo-Yeon Kim, Chan-Hee Jung, Jae Hyeon Kim, Sun Wook Kim, Jae Hoon Chung, Kyungdo Han, Tae Hyuk Kim
Endocrinol Metab. 2022;37(2):281-289.   Published online April 6, 2022
DOI: https://doi.org/10.3803/EnM.2021.1333
  • 5,191 View
  • 142 Download
  • 2 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Hyperthyroidism is associated with an increased glomerular filtration rate (GFR) in the hyperdynamic state, which is reversible after restoring euthyroidism. However, long-term follow-up of renal dysfunction in patients with hyperthyroidism has not been performed.
Methods
This was a retrospective cohort study using the Korean National Health Insurance database and biannual health checkup data. We included 41,778 Graves’ disease (GD) patients and 41,778 healthy controls, matched by age and sex. The incidences of end-stage renal disease (ESRD) were calculated in GD patients and controls. The cumulative dose and duration of antithyroid drugs (ATDs) were calculated for each patient and categorized into the highest, middle, and lowest tertiles.
Results
Among 41,778 GD patients, 55 ESRD cases occurred during 268,552 person-years of follow-up. Relative to the controls, regardless of smoking, drinking, or comorbidities, including chronic kidney disease, GD patients had a 47% lower risk of developing ESRD (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.37 to 0.76). In particular, GD patients with a higher baseline GFR (≥90 mL/min/1.73 m2; HR, 0.33; 95% CI, 0.11 to 0.99), longer treatment duration (>33 months; HR, 0.31; 95% CI, 0.17 to 0.58) or higher cumulative dose (>16,463 mg; HR, 0.29; 95% CI, 0.15 to 0.57) of ATDs had a significantly reduced risk of ESRD.
Conclusion
This was the first epidemiological study on the effect of GD on ESRD, and we demonstrated that GD population had a reduced risk for developing ESRD.

Citations

Citations to this article as recorded by  
  • Renal function changes in patients with subclinical hyperthyroidism: a novel postulated mechanism
    Magdy Mohamed Allam, Hanaa Tarek El-Zawawy, Tarek Hussein El-Zawawy
    Endocrine.2023; 82(1): 78.     CrossRef
  • Effect of Hyperthyroidism on Preventing Renal Insufficiency
    Tae Yong Kim
    Endocrinology and Metabolism.2022; 37(2): 220.     CrossRef
  • Effects and Clinical Value of Peritoneal Dialysis on Water and Water Balance, Adverse Reactions, Quality of Life, and Clinical Prognosis in Patients with Decompensated Chronic Nephropathy: A Systematic Review and Meta-Analysis
    Xichao Wang, Miaomiao Zhang, Na Sun, Wenxiu Chang, Gang Chen
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
Close layer
Close layer
Clinical Study
Relationship of Sarcopenia with Microcirculation Measured by Skin Perfusion Pressure in Patients with Type 2 Diabetes
Chan-Hee Jung, Yoon Young Cho, Dughyun Choi, Bo-Yeon Kim, Chul-Hee Kim, Ji-Oh Mok
Endocrinol Metab. 2020;35(3):578-586.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.679
  • 6,034 View
  • 133 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Few studies have examined the relationship of sarcopenia with the microcirculation. The current study investigated the relationship of sarcopenia with microcirculatory function, as assessed by skin perfusion pressure (SPP), in type 2 diabetes mellitus (T2DM) patients.
Methods
In total, 102 T2DM patients who underwent SPP measurements and bioelectrical impedance analysis (BIA) were enrolled in this cross-sectional study. SPP was assessed using the laser Doppler technique. Sarcopenia was defined as low height-adjusted appendicular muscle mass (men, <7 kg/m2; women, <5.7 kg/m2) using BIA. We divided the participants into two groups based on SPP (≤50 and >50 mm Hg), and an SPP below 50 mm Hg was considered to reflect impaired microcirculation.
Results
Fourteen patients (13.7%) were diagnosed with impaired microcirculatory function of the lower limb based on SPP. The prevalence of sarcopenia in all subjects was 11.8%, but the percentage of patients with an SPP ≤50 mm Hg who had sarcopenia was more than triple that of patients with an SPP >50 mm Hg (28.6% vs. 9.1%, P=0.036). A significant positive correlation was found between SPP and appendicular muscle mass adjusted for height (P=0.041 for right-sided SPP). Multiple logistic regression analysis showed that patients with sarcopenia had an odds ratio of 4.1 (95% confidence interval, 1.01 to 24.9) for having an SPP ≤50 mm Hg even after adjustment for confounding factors.
Conclusion
These results suggest that sarcopenia may be significantly associated with impaired microcirculation in patients with T2DM. Nonetheless, the small number of patients and wide CI require cautious interpretation of the results.

Citations

Citations to this article as recorded by  
  • Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation
    Yuqing Du, Jie Wang, Weijing Fan, Renyan Huang, Hongfei Wang, Guobin Liu
    International Wound Journal.2023; 20(10): 4394.     CrossRef
  • Bioelectrical Impedance Analysis for the Assessment of Body Composition in Sarcopenia and Type 2 Diabetes
    Stefano Sbrignadello, Christian Göbl, Andrea Tura
    Nutrients.2022; 14(9): 1864.     CrossRef
  • Discrimination between possible sarcopenia and metabolic syndrome using the arterial pulse spectrum and machine-learning analysis
    Li-Wei Wu, Te OuYoung, Yu-Chih Chiu, Ho-Feng Hsieh, Hsin Hsiu
    Scientific Reports.2022;[Epub]     CrossRef
  • The prevalence and risk factors of sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
    Yaqin Ai, Ruoxin Xu, Lingping Liu
    Diabetology & Metabolic Syndrome.2021;[Epub]     CrossRef
Close layer
Diabetes
Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus
Chan-Hee Jung, Ji-Oh Mok
Endocrinol Metab. 2020;35(2):260-271.   Published online June 24, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.260
  • 8,420 View
  • 288 Download
  • 15 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   ePub   
It is well known that patients with type 2 diabetes mellitus (T2DM) are at an increased risk of morbidity and mortality from atherosclerotic cardiovascular (CV) complications. Previously, the concept that diabetes mellitus (DM) is a “coronary artery disease (CAD) risk equivalent” was widely accepted, implying that all DM patients should receive intensive management. However, considerable evidence exist for wide heterogeneity in the risk of CV events among T2DM patients and the concept of a “CAD risk equivalent” has changed. Recent guidelines recommend further CV risk stratification in T2DM patients, with treatment tailored to the risk level. Although imaging modalities for atherosclerotic cardiovascular disease (ASCVD) have been used to improve risk prediction, there is currently no evidence that imaging-oriented therapy improves clinical outcomes. Therefore, controversy remains whether we should screen for CVD in asymptomatic T2DM. The coexistence of T2DM and heart failure (HF) is common. Based on recent CV outcome trials, sodium glucose cotransporter-2 inhibitors and glucagon like peptide-1 receptor agonists are recommended who have established ASCVD, indicators of high risk, or HF because of their demonstrated benefits for CVD. These circumstances have led to an increasing emphasis on ASCVD and HF in T2DM patients. In this review, we examine the literature published within the last 5 years on the risk assessment of CVD in asymptomatic T2DM patients. In particular, we review recent guidelines regarding screening for CVD and research focusing on the role of coronary artery calcium, coronary computed tomography angiography, and carotid intima-media thickness in asymptomatic T2DM patients.

Citations

Citations to this article as recorded by  
  • Factors Affecting Arterial Stiffness and Brachial-Ankle Pulse Wave Velocity in Patients With Type 2 Diabetes
    Tomoki Furuya, Shinji Kitahama, Yuma Tamura, Susumu Ogawa, Yuki Nakatani, Takanori Yasu
    Cureus.2024;[Epub]     CrossRef
  • Serum levels of soluble receptor activator for nuclear factor kB ligand play a crucial role in the association of osteoprotegerin with coronary artery disease
    Shaoqiong Zhou, Hui Wen, Bin Wang, Siming Guan, Xin Fang
    Experimental and Therapeutic Medicine.2024;[Epub]     CrossRef
  • Significance of Myocardial Perfusion SPECT (Single-Photon Emission Computed Tomography) Imaging in the Detection of Silent Myocardial Ischemia in Type II Diabetic Patients with Microalbuminuria
    Nayyar Rubab, Muhammad Ijaz Khan, Tania Jabbar, Warda Ahmed, Farkhanda Gillani, Muhammad Shehzad Afzal, Muhammad Iftikhar Khattak, Muhammad Babar Imran
    Pakistan BioMedical Journal.2024; : 17.     CrossRef
  • Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients
    Orsolya-Zsuzsa Akácsos-Szász, Sándor Pál, Kinga-Ilona Nyulas, Enikő Nemes-Nagy, Ana-Maria Fárr, Lóránd Dénes, Mónika Szilveszter, Erika-Gyöngyi Bán, Mariana Cornelia Tilinca, Zsuzsánna Simon-Szabó
    International Journal of Molecular Sciences.2023; 24(5): 4319.     CrossRef
  • Increased soluble endoglin levels in newly-diagnosed type 2 diabetic patients are associated with endothelial dysfunction
    Xiaobing Dou, Xiujing Wang, Xiuhua Yu, Jiaqi Yao, Huiling Shen, Yao Xu, Bojing Zheng, Zhenying Zhang, Qingying Tan, Tianxiao Hu
    Endocrine Journal.2023; 70(7): 711.     CrossRef
  • Effects of hypertension on subcortical nucleus morphological alternations in patients with type 2 diabetes
    Feng Cui, Zhi-Qiang Ouyang, Yi-Zhen Zeng, Bing-Bing Ling, Li Shi, Yun Zhu, He-Yi Gu, Wan-Lin Jiang, Ting Zhou, Xue-Jin Sun, Dan Han, Yi Lu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Coronary Artery Calcium Score as a Sensitive Indicator of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A Long-Term Cohort Study
    Dae-Jeong Koo, Mi Yeon Lee, Sun Joon Moon, Hyemi Kwon, Sang Min Lee, Se Eun Park, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Sung Rae Cho, Young-Hoon Jeong, Eun-Jung Rhee
    Endocrinology and Metabolism.2023; 38(5): 568.     CrossRef
  • Exploring Endothelial Colony-Forming Cells to Better Understand the Pathophysiology of Disease: An Updated Review
    Qiuwang Zhang, Anthony Cannavicci, Michael J. B. Kutryk, Giuseppe Mandraffino
    Stem Cells International.2022; 2022: 1.     CrossRef
  • Recent Insights into the Nutritional Antioxidant Therapy in Prevention and Treatment of Diabetic Vascular Complications: A Comprehensive Review
    Narasimha M. Beeraka, Irina K. Tomilova, Galina A. Batrak, Maria V. Zhaburina, Vladimir N. Nikolenko, Mikhail Y. Sinelnikov, Liudmila M. Mikhaleva
    Current Medicinal Chemistry.2022; 29(11): 1920.     CrossRef
  • Topical Reappraisal of Molecular Pharmacological Approaches to Endothelial Dysfunction in Diabetes Mellitus Angiopathy
    Constantin Munteanu, Mariana Rotariu, Marius-Alexandru Turnea, Aurelian Anghelescu, Irina Albadi, Gabriela Dogaru, Sînziana Calina Silișteanu, Elena Valentina Ionescu, Florentina Carmen Firan, Anca Mirela Ionescu, Carmen Oprea, Gelu Onose
    Current Issues in Molecular Biology.2022; 44(8): 3378.     CrossRef
  • Visfatin is negatively associated with coronary artery lesions in subjects with impaired fasting glucose
    Fei Xu, Xiang Ning, Tong Zhao, Qinghua Lu, Huiqiang Chen
    Open Medicine.2022; 17(1): 1405.     CrossRef
  • Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus
    Dandan Xie, Yutong Li, Murong Xu, Xiaotong Zhao, Mingwei Chen
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Serum netrin and VCAM-1 as biomarker for Egyptian patients with type IΙ diabetes mellitus
    Maher M. Fadel, Faten R. Abdel Ghaffar, Shimaa K. Zwain, Hany M. Ibrahim, Eman AE. badr
    Biochemistry and Biophysics Reports.2021; 27: 101045.     CrossRef
  • Decoding the chemical composition and pharmacological mechanisms of Jiedu Tongluo Tiaogan Formula using high-performance liquid chromatography coupled with network pharmacology-based investigation
    Qi Zhang, Chunli Piao, Wenqi Jin, De Jin, Han Wang, Cheng Tang, Xiaohua Zhao, Naiwen Zhang, Shengnan Gao, Fengmei Lian
    Aging.2021; 13(21): 24290.     CrossRef
Close layer
Clinical Study
Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
Endocrinol Metab. 2020;35(1):165-176.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.165
  • 7,369 View
  • 145 Download
  • 32 Web of Science
  • 34 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

We evaluated the association of visceral-to-subcutaneous fat ratio (VSR) with nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis degree based on noninvasive serum fibrosis markers in the general population with NAFLD.

Methods

This is a cross-sectional study, in 7,465 Korean adults who underwent health screening examinations. NAFLD was defined as fatty liver detected on ultrasonography, and visceral and subcutaneous abdominal fat was measured using computed tomography. We predicted fibrosis based on the fibrosis-4 (FIB-4) score and aspartate aminotransferase-to-platelet ratio index (APRI) and categorized the risk for advanced fibrosis as low, indeterminate, or high.

Results

The multivariable-adjusted prevalence ratios for indeterminate to high risk of advanced fibrosis based on FIB-4, determined by comparing the second, third, and fourth quartiles with the first quartile of VSR, were 3.38 (95% confidence interval [CI], 0.64 to 17.97), 9.41 (95% CI, 1.97 to 45.01), and 19.34 (95% CI, 4.06 to 92.18), respectively. The multivariable-adjusted prevalence ratios for intermediate to high degree of fibrosis according to APRI also increased across VSR quartiles (5.04 [95% CI, 2.65 to 9.59], 7.51 [95% CI, 3.91 to 14.42], and 19.55 [95% CI, 9.97 to 38.34], respectively). High VSR was more strongly associated with the prevalence of NAFLD in nonobese subjects than in obese subjects, and the associations between VSR and intermediate to high probability of advanced fibrosis in NAFLD were stronger in obese subjects than in nonobese subjects.

Conclusion

High VSR values predicted increased NAFLD risk and advanced fibrosis risk with NAFLD, and the predictive value of VSR for indeterminate to high risk of advanced fibrosis was higher in obese subjects than in nonobese subjects.

Citations

Citations to this article as recorded by  
  • Opportunistic Extraction of Quantitative CT Biomarkers: Turning the Incidental Into Prognostic Information
    Mohammad Nazri Md Shah, Raja Rizal Azman, Wai Yee Chan, Kwan Hoong Ng
    Canadian Association of Radiologists Journal.2024; 75(1): 92.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study
    Farid Najafi, Yahya Pasdar, Mehdi Moradi Nazar, Mitra Darbandi
    BMC Endocrine Disorders.2024;[Epub]     CrossRef
  • Regional fat distribution and hepatic fibrosis and steatosis severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Asieh Mansour, Saeed Pourhassan, Hadis Gerami, Mohammad Reza Mohajeri‐Tehrani, Marziye Salahshour, Ali Abbasi, Elham Madreseh, Sayed Mahmoud Sajjadi‐Jazi
    Obesity Science & Practice.2024;[Epub]     CrossRef
  • Visceral to subcutaneous fat area ratio predicts severe abdominal adhesions in definitive surgery for anastomotic fistula after small intestine resection
    Fan Yang, Weiliang Tian, Shikun Luo, Wuhan Li, Guoping Zhao, Risheng Zhao, Tao Tian, Yunzhao Zhao, Zheng Yao, Qian Huang
    Scientific Reports.2024;[Epub]     CrossRef
  • Obesity. Reasons, features and prospects
    E. A. Bondareva, E. A. Troshina
    Obesity and metabolism.2024; 21(2): 174.     CrossRef
  • Differential association of abdominal, liver, and epicardial adiposity with anthropometry, diabetes, and cardiac remodeling in Asians
    Vivian Lee, Yiying Han, Desiree-Faye Toh, Jennifer A. Bryant, Redha Boubertakh, Thu-Thao Le, Calvin W. L. Chin
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Serum immunoglobulin A levels: Diagnostic utility in alcoholic liver disease and association with liver fibrosis in steatotic liver disease
    Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Kazuyoshi Nagata, Kenichi Sawa, Kazutaka Niiya, Kazuhiko Nakao
    Biomedical Reports.2024;[Epub]     CrossRef
  • Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults
    Shuxia Shen, Hangkai Huang, Jinghua Wang, Zexi Tang, Chao Shen, Chengfu Xu
    Digestive Diseases and Sciences.2023; 68(2): 656.     CrossRef
  • Association between Sarcopenic Obesity Status and Nonalcoholic Fatty Liver Disease and Fibrosis
    Wolhwa Song, Sung Hwan Yoo, Jinsun Jang, Su Jung Baik, Byoung Kwon Lee, Hyun Woong Lee, Jong Suk Park
    Gut and Liver.2023; 17(1): 130.     CrossRef
  • Using hyperhomocysteinemia and body composition to predict the risk of non-alcoholic fatty liver disease in healthcare workers
    Xiaoyan Hao, Honghai He, Liyuan Tao, Peng Wang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Visceral and subcutaneous fat, muscle mass, and liver volume as noninvasive predictors of the progress of non-alcoholic fatty liver disease
    Omar M. Mahmoud, Gehad Abd Elaziz Mahmoud, Haisam Atta, Wael A. Abbas, Hanan M. Ahmed, Mohamed A. A. Abozaid
    Egyptian Journal of Radiology and Nuclear Medicine.2023;[Epub]     CrossRef
  • Relationship between metabolic associated fatty liver disease and body fat ratio, visceral fat area, and resting metabolic rate estimated by bioelectrical impedance analysis
    Deng-Hua He, Yong-Zhan Zhang, Liang Xu, Jia-Jia Pei, Ying Zhang, Zhong-Fang Yan
    World Chinese Journal of Digestology.2023; 31(2): 56.     CrossRef
  • Poor glycaemic control and ectopic fat deposition mediates the increased risk of non-alcoholic steatohepatitis in high-risk populations with type 2 diabetes: Insights from Bayesian-network modelling
    T. Waddell, A. Namburete, P. Duckworth, A. Fichera, A. Telford, H. Thomaides-Brears, D. J. Cuthbertson, M. Brady
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Subcutaneous Fat Obesity in a High Body Mass Index Donor Is Not a Contraindication to Living Donor Hepatectomy
    Hirak Pahari, Amey Sonavane, Amruth Raj, Anup Kumar Agrawal, Ambreen Sawant, Deepak Kumar Gupta, Amit Gharat, Vikram Raut, Sorabh Kapoor
    Case Reports in Hepatology.2023; 2023: 1.     CrossRef
  • Comparison of cardiometabolic risk factors between obese and non-obese patients with nonalcoholic fatty liver disease
    Zahra Yari, Danial Fotros, Azita Hekmatdoost
    Scientific Reports.2023;[Epub]     CrossRef
  • Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
    Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
    Clinical and Molecular Hepatology.2023; 29(4): 987.     CrossRef
  • Visceral Adipose Tissue Inflammation and Radiographic Visceral-to-Subcutaneous Adipose Tissue Ratio in Patients with Cirrhosis
    Nghiem B. Ha, Soo-Jin Cho, Yara Mohamad, Dorothea Kent, Grace Jun, Randi Wong, Vivek Swarnakar, Shezhang Lin, Jacquelyn J. Maher, Jennifer C. Lai
    Digestive Diseases and Sciences.2022; 67(7): 3436.     CrossRef
  • The Influence of Obesity and Metabolic Health on Vascular Health
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(1): 1.     CrossRef
  • The effect of combined exercises on the plasma levels of retinol-binding protein 4 and its relationship with insulin resistance and hepatic fat content in postmenopausal women with nonalcoholic fatty liver disease
    Masoumeh NOROUZPOUR, Sayyed M. MARANDI, Mohsen GHANBARZADEH, Abbasali ZARE MAIVAN
    The Journal of Sports Medicine and Physical Fitness.2022;[Epub]     CrossRef
  • The Perirenal Fat Thickness Was Associated with Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Yuxian Yang, Shuting Li, Yuechao Xu, Jing Ke, Dong Zhao
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1505.     CrossRef
  • Visceral adiposity is an independent risk factor for high intra-operative blood loss during living-donor liver transplantation; could preoperative rehabilitation and nutritional therapy mitigate that risk?
    Mahmoud Macshut, Toshimi Kaido, Siyuan Yao, Yosuke Miyachi, Mohamed Sharshar, Sena Iwamura, Masaaki Hirata, Hisaya Shirai, Naoko Kamo, Shintaro Yagi, Shinji Uemoto
    Clinical Nutrition.2021; 40(3): 956.     CrossRef
  • A review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
    Mitra Ahadi, Kasra Molooghi, Negin Masoudifar, Ali Beheshti Namdar, Hassan Vossoughinia, Mohammadreza Farzanehfar
    Journal of Gastroenterology and Hepatology.2021; 36(6): 1497.     CrossRef
  • Quantification of abdominal fat from computed tomography using deep learning and its association with electronic health records in an academic biobank
    Matthew T MacLean, Qasim Jehangir, Marijana Vujkovic, Yi-An Ko, Harold Litt, Arijitt Borthakur, Hersh Sagreiya, Mark Rosen, David A Mankoff, Mitchell D Schnall, Haochang Shou, Julio Chirinos, Scott M Damrauer, Drew A Torigian, Rotonya Carr, Daniel J Rader
    Journal of the American Medical Informatics Association.2021; 28(6): 1178.     CrossRef
  • Hepatic Steatosis in Patients With Single Ventricle and a Fontan Circulation
    David A. Katz, Daniel Peck, Adam M. Lubert, Mathias Possner, Faizeen Zafar, Andrew T. Trout, Joseph J. Palermo, Nadeem Anwar, Jonathan R. Dillman, Adam W. Powell, Stavra A. Xanthakos, Alexander R. Opotowsky, Gruschen Veldtman, Tarek Alsaied
    Journal of the American Heart Association.2021;[Epub]     CrossRef
  • Superficial vs Deep Subcutaneous Adipose Tissue: Sex-Specific Associations With Hepatic Steatosis and Metabolic Traits
    Tessa Brand, Inge Christina Lamberta van den Munckhof, Marinette van der Graaf, Kiki Schraa, Helena Maria Dekker, Leonardus Antonius Bernardus Joosten, Mihai Gheorghe Netea, Niels Peter Riksen, Jacqueline de Graaf, Joseph Henricus Wilhelmus Rutten
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): e3881.     CrossRef
  • Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study
    Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee, Ming-Lung Yu
    PLOS ONE.2021; 16(8): e0255535.     CrossRef
  • Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
    Anne Flint, Grit Andersen, Paul Hockings, Lars Johansson, Anni Morsing, Mads Sundby Palle, Thomas Vogl, Rohit Loomba, Leona Plum‐Mörschel
    Alimentary Pharmacology & Therapeutics.2021; 54(9): 1150.     CrossRef
  • Effects of IL-33 on 3T3-L1 cells and obese mice models induced by a high-fat diet
    Yue Kai, Jingtao Gao, Hu Liu, Yubing Wang, Chenrui Tian, Sheng Guo, Ling He, Min Li, Zhongwei Tian, Xiangfeng Song
    International Immunopharmacology.2021; 101: 108209.     CrossRef
  • Lipid Accumulation Product as an Index for Visceral Obesity and Cardiovascular Risk among a Sample of Obese Egyptian Women
    Nayera E. Hassan, Sahar A. El-Masry, Gamila S. M. El-Saeed, Mohamed S. El Hussieny
    Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 1229.     CrossRef
  • Combined Effects of Dyslipidemia and High Adiposity on the Estimated Glomerular Filtration Rate in a Middle-Aged Chinese Population
    Xichang Wang, Haoyu Wang, Jiashu Li, Xiaotong Gao, Yutong Han, Weiping Teng, Zhongyan Shan, Yaxin Lai
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4513.     CrossRef
  • Determination of “indeterminate score” measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia
    Yasir Mohammed Khayyat
    World Journal of Hepatology.2021; 13(12): 2150.     CrossRef
  • Utility of Liver Function Tests and Fatty Liver Index to Categorize Metabolic Phenotypes in a Mediterranean Population
    Dariusz Narankiewicz, Josefina Ruiz-Nava, Veronica Buonaiuto, María Isabel Ruiz-Moreno, María Dolores López-Carmona, Luis Miguel Pérez-Belmonte, Ricardo Gómez-Huelgas, María Rosa Bernal-López
    International Journal of Environmental Research and Public Health.2020; 17(10): 3518.     CrossRef
Close layer
Diabetes
Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
Chan-Hee Jung
Endocrinol Metab. 2019;34(3):265-267.   Published online September 26, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.3.265
  • 3,813 View
  • 47 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
    Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
    Current Medical Research and Opinion.2021; 37(9): 1529.     CrossRef
Close layer
Clinical Study
Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Bo-Yeon Kim
Endocrinol Metab. 2018;33(3):387-394.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.387
  • 5,840 View
  • 121 Download
  • 36 Web of Science
  • 35 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are expected to improve the liver function of patients with non-alcoholic fatty liver disease (NAFLD) combined type 2 diabetes mellitus (T2DM) by its characteristic mechanism. This study was designed to investigate the effect of dapagliflozin, one of the SGLT2i, on the liver function of T2DM with NAFLD when combined with metformin.

Methods

Among patients who received dual oral hypoglycemic agents within the 3 months of diagnosing NAFLD, patients who had abnormal alanine aminotransferase (ALT) level (>40 IU/L) were included. Patients were divided into two groups: metformin+dapagliflozin group and metformin+dipeptidyl peptidase-4 inhibitors (DPP4i) group. Demographic data, biochemical data and the clinical and treatment histories of all patients were reviewed.

Results

A total of 102 patients were included (dapagliflozin group, n=50; DPP4i group, n=52). Dapagliflozin group showed more weight loss and more ALT decline than DPP4i group (−2.9 kg vs. −0.4 kg, P=0.005; −21.1 U/L vs. −9.5 U/L, P=0.008, respectively) and the proportion of patients with ALT normalization after treatment was also significantly higher in the dapagliflozin group (80.0% vs. 61.5%, P=0.041). The effect of dapagliflozin with metformin on ALT normalization remained significant after adjustment for confounding variables including body weight loss (odds ratio, 3.489; P=0.046).

Conclusion

ALT improvement was statistically significant in the dapagliflozin than the DPP4i when combined with metformin and the result was consistent after adjustment for confounding variables including body weight loss.

Citations

Citations to this article as recorded by  
  • The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
    Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi, Theodoros Androutsakos
    European Journal of Clinical Pharmacology.2024; 80(1): 127.     CrossRef
  • Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
    Hirokazu Takahashi, Keiko Asakawa, Yoshinori Kosakai, Takumi Lee, Mitsuhiro Rokuda
    Diabetes, Obesity and Metabolism.2024; 26(3): 997.     CrossRef
  • Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study
    Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Antonio Segura Fragoso, Verónica Fernández-Pascual, Beatriz Sánchez-Sánchez, María Inmaculada Cervera-Pérez, Francisco Javier Alonso-Moreno, Ezequiel Arranz-Martínez, Alfonso Bar
    Clínica e Investigación en Arteriosclerosis.2024;[Epub]     CrossRef
  • Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
    Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, Erica Vetrano, Giulia Medicamento, Carlo Acierno, Luca Rinaldi, Aldo Marrone, Teresa Salvatore, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso
    Biomedicines.2023; 11(2): 322.     CrossRef
  • Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
    Yong Zhang, Jie Xu, Di Zhou, Tingting Ye, Puqing Zhou, Zuofeng Liu, Xinyuan Liu, Zinan Wang, Tianmiao Hua, Zhenghao Zhang, Qingyan Sun
    Molecular Medicine.2023;[Epub]     CrossRef
  • Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review
    Agnieszka Polecka, Natalia Olszewska, Łukasz Danielski, Ewa Olszewska
    Journal of Clinical Medicine.2023; 12(19): 6139.     CrossRef
  • Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
    Iryna Kostitska, Nadia Protas, Liliia Petrovska
    Diabetes Obesity Metabolic Syndrome.2023; (5): 8.     CrossRef
  • Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
    Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
    International Journal of Diabetes in Developing Countries.2022; 42(2): 290.     CrossRef
  • The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis
    Manqiu Mo, Zichun Huang, Yuzhen Liang, Yunhua Liao, Ning Xia
    Digestive and Liver Disease.2022; 54(4): 461.     CrossRef
  • Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation
    Reem M. Hazem, Ahmed Z. Ibrahim, Dina A. Ali, Yasser M. Moustafa
    International Immunopharmacology.2022; 104: 108503.     CrossRef
  • SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
    Theodoros Androutsakos, Narjes Nasiri-Ansari, Athanasios-Dimitrios Bakasis, Ioannis Kyrou, Efstathios Efstathopoulos, Harpal S. Randeva, Eva Kassi
    International Journal of Molecular Sciences.2022; 23(6): 3107.     CrossRef
  • Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice
    Panshuang Qiao, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial
    Yumie Takeshita, Masao Honda, Kenichi Harada, Yuki Kita, Noboru Takata, Hiromasa Tsujiguchi, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
    Diabetes Care.2022; 45(9): 2064.     CrossRef
  • Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes
    Vincenzo Maria Monda, Sandro Gentile, Francesca Porcellati, Ersilia Satta, Alessandro Fucili, Marcello Monesi, Felice Strollo
    Advances in Therapy.2022; 39(11): 4837.     CrossRef
  • Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms
    Hager H. Shaaban, Ibrahim Alzaim, Ahmed El-Mallah, Rania G. Aly, Ahmed F. El-Yazbi, Ahmed Wahid
    Life Sciences.2022; 308: 120956.     CrossRef
  • The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
    Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, Evangelos Cholongitas
    Journal of Gastroenterology and Hepatology.2021; 36(4): 893.     CrossRef
  • Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
    Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, Yip Han Chin, Yi Fen Low, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Chin Meng Khoo
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
    Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho, Adelino Leite‐Moreira
    Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
  • Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
    Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili, Stephen N. Davis
    Expert Review of Clinical Pharmacology.2021; 14(7): 837.     CrossRef
  • Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Won Euh, Soo Lim, Jin-Wook Kim
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway
    Jingyi Luo, Pengbo Sun, Yangyang Wang, Yang Chen, Yaoyun Niu, Yipei Ding, Naihan Xu, Yaou Zhang, Weidong Xie
    European Journal of Pharmacology.2021; 907: 174304.     CrossRef
  • The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
    Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, Apinya Leerapun, Arintaya Phrommintikul, Supawan Buranapin, Nipon Chattipakorn, Satawat Thongsawat
    Journal of Gastroenterology and Hepatology.2021; 36(10): 2952.     CrossRef
  • Possible Preventative/Rehabilitative Role of Gliflozins in OSA and T2DM. A Systematic Literature Review-Based Hypothesis
    Vincenzo Maria Monda, Francesca Porcellati, Felice Strollo, Alessandro Fucili, Marcello Monesi, Ersilia Satta, Sandro Gentile
    Advances in Therapy.2021; 38(8): 4195.     CrossRef
  • Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B
    Lilian Yan Liang, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Terry Cheuk‐Fung Yip, Yee‐Kit Tse, Grace Chung‐Yan Lui, Henry Lik‐Yuen Chan, Grace Lai‐Hung Wong
    GastroHep.2021; 3(4): 261.     CrossRef
  • Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
    Kanokwan Pinyopornpanish, Apinya Leerapun, Kanokporn Pinyopornpanish, Nipon Chattipakorn
    Gut and Liver.2021; 15(6): 827.     CrossRef
  • The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
    F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, Randall L. Halcomb
    Journal of Medicinal Chemistry.2020; 63(10): 5031.     CrossRef
  • SGLT2 Inhibitors in Liver Patients
    John Chen Hsiang, Vincent Wai-Sun Wong
    Clinical Gastroenterology and Hepatology.2020; 18(10): 2168.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2019; 92: 82.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
    Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
    Diabetes & Metabolism Journal.2019; 43(2): 127.     CrossRef
  • Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet
    Fan Zheng, Ying Cai
    Lipids in Health and Disease.2019;[Epub]     CrossRef
  • The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
    Chan-Hee Jung, Ji-Oh Mok
    Journal of Obesity & Metabolic Syndrome.2019; 28(1): 18.     CrossRef
  • Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
    Niki Katsiki, Nikolaos Perakakis, Christos Mantzoros
    Metabolism.2019; 98: iii.     CrossRef
  • Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
    Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
    Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef
  • Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
    A.J. Scheen
    Diabetes & Metabolism.2019; 45(3): 213.     CrossRef
Close layer
Close layer
Obesity and Metabolism
Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance
Kyu-Jin Kim, Bo-Yeon Kim, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Chan-Hee Jung
Endocrinol Metab. 2015;30(3):318-325.   Published online May 18, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.3.318
  • 4,469 View
  • 46 Download
  • 10 Web of Science
  • 12 Crossref
AbstractAbstract PDFPubReader   
Background

Thyroid hormones can influence energy metabolism and insulin sensitivity via their interaction with adipocytokines and gut hormones. The aims of this study were to evaluate differences in serum ghrelin and leptin concentrations according to thyroid hormone levels, and to investigate the correlation of insulin resistance.

Methods

A total of 154 patients (57 hyperthyroid patients, 61 euthyroid patients, and 36 hypothyroid patients; mean age, 47.9 years) were enrolled. Serum leptin, ghrelin, and insulin levels were measured and insulin resistance was calculated using the formula of the homeostasis model assessment of insulin resistance (HOMA-IR).

Results

There were no differences in mean concentrations of ghrelin or leptin among the three groups. There were no significant differences in insulin levels between the groups (P=0.06), although hyperthyroid patients had borderline statistically significantly higher levels of insulin than did euthyroid subjects by post hoc test (26.4 µIU/mL vs. 16.1 µIU/mL, P=0.057). Regarding HOMA-IR index, the mean levels were highest in the hyperthyroid group among those of the three groups (hyperthyroid vs. euthyroid vs. hypothyroid, 6.7 vs. 3.8 vs. 4.4, P=0.068). Plasma levels of ghrelin were significantly negatively correlated with age, insulin, glucose, body mass index (BMI), and HOMA-IR. Plasma levels of leptin showed significant positive correlation with BMI and triglyceride. There were no significant correlations among thyroid hormone, thyrotropin, ghrelin, leptin, or insulin.

Conclusion

The present study found that serum ghrelin, leptin, and insulin levels didn't differ according to thyroid function conditions. Further studies with larger numbers of patients are required to establish a direct relationship between plasma ghrelin, leptin, and thyroid hormone.

Citations

Citations to this article as recorded by  
  • Thyroid disorders and gastrointestinal dysmotility: an old association
    Guang-Meng Xu, Ming-Xin Hu, Si-Yu Li, Xuan Ran, Hao Zhang, Xiang-Fu Ding
    Frontiers in Physiology.2024;[Epub]     CrossRef
  • Insulin resistance, leptin and adiponectin in lean and hypothyroid children and adolescents with obesity
    Doaa El Amrousy, Dalia El-Afify, Shaimaa Salah
    BMC Pediatrics.2022;[Epub]     CrossRef
  • Mediators of energy homeostasis in hyperthyroidism
    Avinash Patil, Suresh Vaikkakara, Mani Deepthi Dasari, Sandeep Ganta, Alok Sachan, Kiranmayi S. Vinapamula
    Archives of Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • STUDY OF GHRELIN LEVELS IN HYPOTHYROID PATIENTS BEFORE AND AFTER TREATMENT
    Peeyush Yadav, G. G. Kaushik
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 52.     CrossRef
  • Acylated Ghrelin Attenuates l-Thyroxin–induced Cardiac Damage in Rats by Antioxidant and Anti-inflammatory Effects and Downregulating Components of the Cardiac Renin–angiotensin System
    Rehab Badi
    Journal of Cardiovascular Pharmacology.2021; 78(3): 422.     CrossRef
  • Experimental hypothyroidism in adult male rats: the effects of Artemisia dracunculus aqueous extract on serum thyroid hormones, lipid profile, leptin, adiponectin, and antioxidant factors
    Mohammad Mohsen Mohammadi, Mahdi Saeb, Saeed Nazifi
    Comparative Clinical Pathology.2020; 29(2): 485.     CrossRef
  • Leptin, neuropeptide Y (NPY), melatonin and zinc levels in experimental hypothyroidism and hyperthyroidism: relation with melatonin and the pineal gland
    Abdulkerim Kasım Baltaci, Rasim Mogulkoc
    Hormone Molecular Biology and Clinical Investigation.2018;[Epub]     CrossRef
  • Leptin, NPY, Melatonin and Zinc Levels in Experimental Hypothyroidism and Hyperthyroidism: The Relation to Zinc
    Abdulkerim Kasım Baltaci, Rasim Mogulkoc
    Biochemical Genetics.2017; 55(3): 223.     CrossRef
  • Thyroid Hormone Regulation and Insulin Resistance: Insights From Animals Naturally Adapted to Fasting
    Bridget Martinez, Rudy M. Ortiz
    Physiology.2017; 32(2): 141.     CrossRef
  • Role of the Orexin System on the Hypothalamus-Pituitary-Thyroid Axis
    Antonietta Messina, Carolina De Fusco, Vincenzo Monda, Maria Esposito, Fiorenzo Moscatelli, Anna Valenzano, Marco Carotenuto, Emanuela Viggiano, Sergio Chieffi, Vincenzo De Luca, Giuseppe Cibelli, Marcellino Monda, Giovanni Messina
    Frontiers in Neural Circuits.2016;[Epub]     CrossRef
  • Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance (Endocrinol Metab2015;30:318-25, Kyu-Jin Kim et al.)
    Jin Hwa Kim
    Endocrinology and Metabolism.2015; 30(4): 631.     CrossRef
  • Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance (Endocrinol Metab2015;30:318-25, Kyu-Jin Kim et al.)
    Chan-Hee Jung
    Endocrinology and Metabolism.2015; 30(4): 633.     CrossRef
Close layer
Adrenal gland
Clinical Characteristics and Metabolic Features of Patients with Adrenal Incidentalomas with or without Subclinical Cushing's Syndrome
Bo-Yeon Kim, A-Reum Chun, Kyu-Jin Kim, Chan-Hee Jung, Sung Koo Kang, Ji-Oh Mok, Chul-Hee Kim
Endocrinol Metab. 2014;29(4):457-463.   Published online December 29, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.4.457
  • 4,597 View
  • 46 Download
  • 23 Web of Science
  • 20 Crossref
AbstractAbstract PDFPubReader   
Background

The aim of this study was to examine the clinical characteristics of adrenal incidentalomas discovered by computed tomography (CT) and to investigate metabolic features of subclinical Cushing's syndrome (SCS) in patients with adrenal incidentalomas in a tertiary hospital in Korea.

Methods

This retrospective study examined the clinical aspects of 268 patients with adrenal incidentalomas discovered by CT at Soonchunhyang University Bucheon Hospital. Clinical data and endocrine function of the patients as well as histological findings were obtained from medical records, while anatomic characteristics were analyzed by reviewing imaging studies. Hormonal tests for pheochromocytoma, Cushing's syndrome, and aldosterone-secreting adenoma were performed.

Results

Most (n=218, 81.3%) cases were nonfunctioning tumors. Of the 50 patients with functioning tumors (18.7%), 19 (7.1%) were diagnosed with SCS, nine (3.4%) with overt Cushing's syndrome, 12 (4.5%) with primary aldosteronism, and 10 (3.7%) with pheochromocytoma. Malignant tumors (both primary and metastatic) were rare (n=2, 0.7%). Body mass index, fasting glucose, hemoglobin A1c, and total cholesterol were significantly higher in patients with SCS in comparison with those with nonfunctioning tumors. The prevalence of type 2 diabetes mellitus and hypertension were significantly higher in patients with SCS compared with those with nonfunctioning tumors.

Conclusion

Functioning tumors, especially those with subclinical cortisol excess, are commonly found in patients with adrenal incidentalomas, although malignancy is rare. In addition, patients with SCS in adrenal incidentalomas have adverse metabolic and cardiovascular profiles.

Citations

Citations to this article as recorded by  
  • Management of Adrenal Cortical Adenomas: Assessment of Bone Status in Patients with (Non-Functioning) Adrenal Incidentalomas
    Alexandra-Ioana Trandafir, Mihaela Stanciu, Simona Elena Albu, Vasile Razvan Stoian, Irina Ciofu, Cristian Persu, Claudiu Nistor, Mara Carsote
    Journal of Clinical Medicine.2023; 12(13): 4244.     CrossRef
  • Adrenalectomy improves blood pressure control in nonfunctioning adrenal incidentalomas and glycemic and lipid control in patients with autonomous cortisol secretion
    Marta Araujo-Castro, César Mínguez Ojeda, María Noelia Sánchez Ramírez, Victoria Gómez Dos Santos, Eider Pascual-Corrrales, María Fernández-Argüeso
    Endocrine.2022; 78(1): 142.     CrossRef
  • Depression was associated with younger age, female sex, obesity, smoking, and physical inactivity, in 1027 patients with newly diagnosed type 2 diabetes: a Swedish multicentre cross-sectional study
    Eva O. Melin, Pär Wanby, Thomas Neumark, Sara Holmberg, Ann-Sofi Nilsson Neumark, Karin Johansson, Mona Landin-Olsson, Hans Thulesius, Magnus Hillman, Maria Thunander
    BMC Endocrine Disorders.2022;[Epub]     CrossRef
  • Metabolic syndrome and Visceral Adiposity Index in non-functional adrenal adenomas
    Savas Karatas, Yalcin Hacioglu, Selvihan Beysel
    Archives of Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • DHEAS and Differential Blood Counts as Indirect Signs of Glucocorticoid Excess in Adrenal Non-Producing Adenomas
    Eliza P. Winzinger, Hana Jandikova, Matthias Haase, Andreas Knauerhase, Tudor Winzinger, Matthias Schott, Holger S. Willenberg
    Hormone and Metabolic Research.2021; 53(08): 512.     CrossRef
  • Links between aldosterone excess and metabolic complications: A comprehensive review
    C. Bothou, F. Beuschlein, A. Spyroglou
    Diabetes & Metabolism.2020; 46(1): 1.     CrossRef
  • Presentation and outcome of patients with an adrenal mass: A retrospective observational study
    Nadeema Rafiq, Tauseef Nabi, SajadAhmad Dar, Shahnawaz Rasool
    Clinical Cancer Investigation Journal.2020; 9(5): 198.     CrossRef
  • Malignancy Risk and Hormonal Activity of Adrenal Incidentalomas in a Large Cohort of Patients from a Single Tertiary Reference Center
    Ewa Cyranska-Chyrek, Ewelina Szczepanek-Parulska, Michal Olejarz, Marek Ruchala
    International Journal of Environmental Research and Public Health.2019; 16(10): 1872.     CrossRef
  • Biochemical and clinical characteristics of patients with primary aldosteronism – single centre experience
    Nataša Vujačić, Ivan Paunović, Aleksandar Diklić, Vladan Živaljević, Nikola Slijepčević, Nevena Kalezić, Mirjana Stojković, Miloš Stojanović, Biljana Beleslin, Miloš Žarković, Jasmina Ćirić
    Journal of Medical Biochemistry.2019;[Epub]     CrossRef
  • The association of low muscle mass with soluble receptor for advanced glycation end products (sRAGE): The Korean Sarcopenic Obesity Study (KSOS)
    Tae Nyun Kim, Man Sik Park, Eun Joo Lee, Hye Soo Chung, Hye Jin Yoo, Hyun Joo Kang, Wook Song, Sei Hyun Baik, Kyung Mook Choi
    Diabetes/Metabolism Research and Reviews.2018;[Epub]     CrossRef
  • Nonfunctioning adrenal incidentaloma: A novel predictive factor for metabolic syndrome
    Emanuela M. Ribeiro Cavalari, Marcela P. de Paula, Mariana Arruda, Nathália Carraro, Arthur Martins, Kamila de Souza, Maria C. Coelho, Nathalie Anne de Oliveira e Silva de Morais, Aline B. Moraes, Leonardo Vieira Neto
    Clinical Endocrinology.2018; 89(5): 586.     CrossRef
  • Guidelines for the Management of Adrenal Incidentaloma: the Korean Endocrine Society, Committee of Clinical Practice Guidelines
    Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang-Wan Kim, Soo-Kyung Kim, Hae-Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung-Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
    The Korean Journal of Medicine.2017; 92(1): 4.     CrossRef
  • Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
    Carla Scaroni, Marialuisa Zilio, Michelangelo Foti, Marco Boscaro
    Endocrine Reviews.2017; 38(3): 189.     CrossRef
  • Clinical Guidelines for the Management of Adrenal Incidentaloma
    Jung-Min Lee, Mee Kyoung Kim, Seung-Hyun Ko, Jung-Min Koh, Bo-Yeon Kim, Sang Wan Kim, Soo-Kyung Kim, Hae Jin Kim, Ohk-Hyun Ryu, Juri Park, Jung Soo Lim, Seong Yeon Kim, Young Kee Shong, Soon Jib Yoo
    Endocrinology and Metabolism.2017; 32(2): 200.     CrossRef
  • Increased 3β-hydroxysteroid dehydrogenase 2 and 17α-hydroxylase activities in a virilized adolescent female with adrenal adenoma: A case report
    GUOQING YANG, JINGTAO DOU, XIAOLIN ZHANG, WEIJUN GU, ZHAOHUI LV, JIN DU, JIANMING BA, YIMING MU, JUMING LU
    Experimental and Therapeutic Medicine.2016; 11(2): 530.     CrossRef
  • Subclinical hypercortisolism: a state, a syndrome, or a disease?
    Guido Di Dalmazi, Renato Pasquali, Felix Beuschlein, Martin Reincke
    European Journal of Endocrinology.2015; 173(4): M61.     CrossRef
  • Metabolic comorbidities in Cushing's syndrome
    Francesco Ferraù, Márta Korbonits
    European Journal of Endocrinology.2015; 173(4): M133.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Incidentally Discovered Aldosterone and Cortisol Cosecreting Adrenal Cortical Adenoma
    Ji Yun Bae, Jihyun Lee, Yeji Han, Seog Ki Min, Min-Sun Cho, Yeon-Ah Sung
    The Ewha Medical Journal.2015; 38(3): 129.     CrossRef
  • Subclinical Cushing's Syndrome and Metabolic Disorder
    Ji Cheol Bae
    Endocrinology and Metabolism.2014; 29(4): 441.     CrossRef
Close layer
Close layer
Close layer
Obesity and Metabolism
Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes
Chan-Hee Jung, Ae-Rin Baek, Kyu-Jin Kim, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
Endocrinol Metab. 2013;28(4):309-319.   Published online December 12, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.4.309
  • 4,867 View
  • 39 Download
  • 22 Crossref
AbstractAbstract PDFPubReader   
Background

It is not clear whether microangiopathies are associated with subclinical atherosclerosis in type 2 diabetes mellitus (T2DM). We investigated the relation of cardiac autonomic neuropathy (CAN) and other microangiopathies with carotid atherosclerosis in T2DM.

Methods

A total of 131 patients with T2DM were stratified by mean carotid intima-media thickness (CIMT) ≥ or <1.0 mm and the number of carotid plaques. CAN was assessed by the five standard cardiovascular reflex tests according to the Ewing's protocol. CAN was defined as the presence of at least two abnormal tests or an autonomic neuropathy points ≥2. Diabetic microangiopathies were assessed.

Results

Patients with CAN comprised 77% of the group with mean CIMT ≥1.0 mm, while they were 29% of the group with CIMT <1.0 mm (P=0.016). Patients with diabetic retinopathy (DR) comprised 68% of the group with CIMT ≥1.0 mm, while they were 28% of the group without CIMT thickening (P=0.003). Patients with CAN comprised 51% of the group with ≥2 carotid plaques, while they were 23% of the group with ≤1 carotid plaque (P=0.014). In multivariable adjusted logistic regression analysis, the patients who presented with CAN showed an odds ratio [OR] of 8.6 (95% confidence interval [CI], 1.6 to 44.8) for CIMT thickening and an OR of 2.9 (95% CI, 1.1 to 7.5) for carotid plaques. Furthermore, patients with DR were 3.8 times (95% CI, 1.4 to 10.2) more likely to have CIMT thickening.

Conclusion

These results suggest that CAN is associated with carotid atherosclerosis, represented as CIMT and plaques, independent of the traditional cardiovascular risk factors in T2DM. CAN or DR may be a determinant of subclinical atherosclerosis in T2DM.

Citations

Citations to this article as recorded by  
  • Common carotid artery intima media thickness (CIMT) in patients with prediabetes and newly diagnosed type 2 diabetes mellitus
    Antoaneta Gateva, Yavor Assyov, Vera Karamfilova, Zdravko Kamenov
    Journal of Diabetes and its Complications.2024; 38(7): 108766.     CrossRef
  • Carotid atherosclerosis: An independent risk factor for small fiber nerve dysfunction in patients with type 2 diabetes mellitus
    Simin Guo, Yali Jing, Chenxi Li, Dalong Zhu, Weimin Wang
    Journal of Diabetes Investigation.2023; 14(2): 289.     CrossRef
  • Evaluating Diagnostic Ultrasound of the Vagus Nerve as a Surrogate Marker for Autonomic Neuropathy in Diabetic Patients
    Bianka Heiling, Adriana Karl, Nadin Fedtke, Nicolle Müller, Christof Kloos, Alexander Grimm, Hubertus Axer
    Medicina.2023; 59(3): 525.     CrossRef
  • Albuminuria but not low eGFR is closely associated with atherosclerosis in patients with type 2 diabetes: an observational study
    Jun-Wei Wang, Jiang-Feng Ke, Zhi-Hui Zhang, Jun-Xi Lu, Lian-Xi Li
    Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
  • Predictive Value of the Advanced Lipoprotein Profile and Glycated Proteins on Diabetic Retinopathy
    Josep Julve, Joana Rossell, Eudald Correig, Marina Idalia Rojo-Lopez, Nuria Amigó, Marta Hernández, Alicia Traveset, Marc Carbonell, Nuria Alonso, Didac Mauricio, Esmeralda Castelblanco
    Nutrients.2022; 14(19): 3932.     CrossRef
  • The relationship between carotid disease and retinopathy in diabetes: a systematic review
    Jocelyn J. Drinkwater, Timothy M. E. Davis, Wendy A. Davis
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Carotid Disease and Retinal Optical Coherence Tomography Angiography Parameters in Type 2 Diabetes: The Fremantle Diabetes Study Phase II
    Jocelyn J. Drinkwater, Fred K. Chen, Alison M. Brooks, Brad T. Davis, Angus W. Turner, Timothy M.E. Davis, Wendy A. Davis
    Diabetes Care.2020; 43(12): 3034.     CrossRef
  • Diabetic foot – invalidating complication of diabetes mellitus
    Oana Manuela Spălăţelu, Sergiu Chirila, Leonard Gurgas, Vasile Sârbu
    Medic.ro.2019; 3(129): 40.     CrossRef
  • Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus
    Ji Eun Jun, Seung-Eun Lee, Min Sun Choi, Sung Woon Park, You-Cheol Hwang, Jae Hyeon Kim
    Cardiovascular Diabetology.2019;[Epub]     CrossRef
  • Association of carotid intima-media thickness with exercise tolerance test in type 2 diabetic patients
    Ali Momeni, Abdolmajid Taheri, Maryam Mansuri, Ali Bazdar, Morteza Sedehi, Masoud Amiri
    IJC Heart & Vasculature.2018; 21: 74.     CrossRef
  • Cardiac autonomic neuropathy may play a role in pathogenesis of atherosclerosis in type 1 diabetes mellitus
    Sarka Mala, Veronika Potockova, Lucie Hoskovcova, Pavlina Pithova, Marek Brabec, Jaroslava Kulhankova, Radan Keil, Lucie Riedlbauchova, Jan Broz
    Diabetes Research and Clinical Practice.2017; 134: 139.     CrossRef
  • Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes
    Akihiko Ando, Michiaki Miyamoto, Kazuhiko Kotani, Kenta Okada, Shoichiro Nagasaka, Shun Ishibashi
    Journal of Diabetes Research.2017; 2017: 1.     CrossRef
  • Cardiac Involvement in Peripheral Neuropathies
    Ahmet Z. Burakgazi, Soufian AlMahameed
    Journal of Clinical Neuromuscular Disease.2016; 17(3): 120.     CrossRef
  • The relationship between vitamin D status and cardiac autonomic neuropathy in patients with type 2 diabetes mellitus
    Chan-Hee Jung, Sang-Hee Jung, Kyu-Jin Kim, Bo-Yeon Kim, Chul-Hee Kim, Sung-Koo Kang, Ji-Oh Mok
    Diabetes and Vascular Disease Research.2015; 12(5): 342.     CrossRef
  • Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes
    Na Fang, Wei Han, Dandan Gong, Zou Chen, Yu Fan
    Medicine.2015; 94(44): e1920.     CrossRef
  • Cardiovascular complications in patients with autonomic failure
    Valeria Milazzo, Cristina Di Stefano, Alberto Milan, Agnese Ravera, Gabriele Sobrero, Luca Sabia, Franco Veglio, Simona Maule
    Clinical Autonomic Research.2015; 25(3): 133.     CrossRef
  • Association of heart rate with albuminuria in a general adult population: the 2011 Korea National Health and Nutrition Examination Survey
    H. S. Choi, J. W. Hong, J. H. Lee, J. H. Noh, D. J. Kim
    Internal Medicine Journal.2015; 45(4): 428.     CrossRef
  • Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy
    Núria Alonso, Alicia Traveset, Esther Rubinat, Emilio Ortega, Nuria Alcubierre, Jordi Sanahuja, Marta Hernández, Angels Betriu, Carmen Jurjo, Elvira Fernández, Didac Mauricio
    Cardiovascular Diabetology.2015;[Epub]     CrossRef
  • Letter: Association between Cardiac Autonomic Neuropathy, Diabetic Retinopathy and Carotid Atherosclerosis in Patients with Type 2 Diabetes (Endocrinol Metab 2013;28:309-19, Chan-Hee Jung et al.)
    Hyun-Kyung Chung
    Endocrinology and Metabolism.2014; 29(1): 101.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
  • Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment
    M.K. Kim, K.-J. Yun, H.J. Chun, E.-H. Jang, K.-D. Han, Y.-M. Park, K.-H. Baek, K.-H. Song, B.-Y. Cha, C.S. Park, H.-S. Kwon
    Diabetes & Metabolism.2014; 40(6): 459.     CrossRef
  • Association between Brachial-Ankle pulse wave velocity and cardiac autonomic neuropathy in type 2 diabetes
    Nan Wu, Xiaoling Cai, Kuanping Ye, Yintao Li, Min He, Weiwei Zhao, Renming Hu
    Diabetology & Metabolic Syndrome.2014;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP